This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
COL6A2 · Western blot design guide
COL6A2 Western Blot Planning Guide
Plan a COL6A2 Western blot around the catalog-observed 108.6 kDa band, image-backed A03194-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
COL6A2 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 108.6 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Adipose tissue | |
| Negative control | Cerebral cortex |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 108.6 kDa |
| ⓘ | Localization | Secreted, extracellular space, extracellular matrix / Membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated COL6A2 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adipose tissue |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A03194-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected COL6A2 Western Blot Band Size?
Use the product-observed 108.6 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 108.6 kDa | Matches the authoritative product WB observation. |
| 108.6 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected COL6A2 appearancePlan around 108.6 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 108.6 kDa; use this as the primary experimental expectation. |
| Calculated mass | 108.6 kDa from UniProt P12110; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A03194-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 108.6 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing COL6A2 band
A03194-2 · COL6A2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for COL6A2 Western blot
🧪Use Adipose tissue as the first positive-control candidate and Cerebral cortex as the HPA Not detected negative candidate.
Positive control: Adipose tissue (High)
Negative control: Cerebral cortex (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for COL6A2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | High | Protein (HPA) | HPA → |
| Kidney | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced COL6A2 Western Blot Tips
Deeper troubleshooting and optimisation questions for COL6A2, answered from its protein features.
Which band should guide the blot?
Use 108.6 kDa, the observation attached to the authoritative A03194-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 108.6 kDa expectation.
Which positive control should I start with?
Start with Adipose tissue, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Cerebral cortex as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for COL6A2 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A03194-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
COL6A2 Western Blot Reagents
Human-reactive COL6A2 Western blot reagents with authoritative product imagery.
Real WB data
Anti-Collagen VI/COL6A2 Antibody Picoband®
Cat # A03194-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P12110
- Human Protein Atlas — COL6A2
- A03194-2 product record
- PMC9732579 — The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma (Frontiers in oncology, 2022)
- PMC12664722 — COL6A2 drives clear cell renal cell carcinoma progression via integrin-dependent modulation of Wnt/β-catenin signaling (Journal of Cancer, 2025)
- PMC7712461 — PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression (Matrix biology : journal of the International Society for Matrix Biology, 2020)